Apimeds Pharmaceuticals US, Inc. (APUS)

NYSEAMERICAN: APUS · Real-Time Price · USD
1.860
-0.080 (-4.12%)
Sep 4, 2025, 4:00 PM - Market closed
-4.12%
Market Cap23.39M
Revenue (ttm)n/a
Net Income (ttm)-3.71M
Shares Out 12.58M
EPS (ttm)-0.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume31,117
Open1.980
Previous Close1.940
Day's Range1.800 - 1.980
52-Week Range1.370 - 4.000
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateAug 19, 2025

About APUS

Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, a purified, pharmaceutical grade venom of the Apis mellifera, or honeybee for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company has a strategic alliance with University of Alabama for the development of ai² future labs program. The company was incorporated in 2020 and is based in Matawan, N... [Read more]

Sector Healthcare
IPO Date May 9, 2025
Employees 2
Stock Exchange NYSEAMERICAN
Ticker Symbol APUS
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs

MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the launch of its ai² Future Labs program in partnership with The University of Alaba...

10 days ago - Business Wire

Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division

MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical-stage biopharmaceutical company developing Apitox, an intradermally admi...

7 weeks ago - Business Wire

Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering

Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the pr...

4 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: Sizable Insurance IPOs Deliver Solid Trading

A few new issuers went public this past week, joined by two SPACs. Three IPOs are scheduled to list in the week ahead, although some small deals may join the calendar at the last minute. Street resear...

Other symbols: AHLAIIANTAETOR
4 months ago - Seeking Alpha

Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering

Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the pr...

4 months ago - GlobeNewsWire

Inflammation-focused biotech Apimeds Pharmaceuticals US files for a $12 million IPO

Apimeds Pharmaceuticals US, a clinical stage biotech developing a bee venom-based treatment for inflammation, filed on Wednesday with the SEC to raise up to $12 million in an initial public offering.

1 year ago - Renaissance Capital

Apimeds Pharmaceuticals US IPO Registration Document (S-1)

Apimeds Pharmaceuticals US has filed to go public with an IPO on the NYSE American

1 year ago - SEC